Cannabis Bioscience International Holdings, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cannabis Bioscience International Holdings, Inc. (CBIH) provides educational systems focused on medical cannabis, clinical research services, and related healthcare solutions in the United States and internationally. The company offers multilevel educational services through its Pharmacology University, including continuing medical education courses for physicians, continuing legal education for attorneys, certification programs for physicians and industry workers, general seminars, and on-site training; consulting, digital publishing, marketing, and franchising related to medical cannabis; phase I to IV clinical research studies through its Alpha Research Institute, LLC, serving clients such as Biovt, Philip Morris, Pfizer, and Inventiva; fertility and sleep center services addressing sleep disorders and infertility; and sales of CBD products. Founded in 2003 and headquartered in Houston, Texas, CBIH operates primarily in the cannabis and biotechnology sectors, targeting entrepreneurs, medical professionals, legal experts, cultivators, dispensary technicians, manufacturers, and patients in the United States, Latin America, and select international markets. In January 2025, CBIH announced a strategic partnership with Stephen Gould, an 80-year-old industry veteran with operations in over 40 locations across six countries, to manufacture and distribute its proprietary medical formulations, with the first product wave launching in Q1 2025 to accelerate market delivery. The company previously rebranded from China Infrastructure Construction Corp. (CHNC) and Hippocrates Direct Healthcare, Inc., culminating in its current name adoption in December 2022, alongside a merger with Pharmacology University to bolster its cannabis clinical trials capabilities. Additional recent developments include engaging StoneBridge Advisory in May 2024 for comprehensive company valuation and appointing Charles Tamburello to its board to strengthen M&A strategy, as well as launching a statewide Texas educational seminar series in September 2025 on TCUP expansion following House Bill 46 approval.
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
CBIH Charts Path to Future Leadership in Cannabis Medicine
CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
Vita Biotech Retains CBIH Services for Clinical Studies